Short answer
Alnylam Pharmaceuticals (ALNY) filed an 8-K current report with the SEC on May 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Board expanded from 10 to 11 directors with Benjamin F. Cravatt, Ph.D. appointed through the 2028 annual meeting.
Alnylam Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 10 to 11 directors with Benjamin F. Cravatt, Ph.D. appointed through the 2028 annual meeting
- Cravatt joins the Science and Technology Committee, adding specialized scientific expertise to board oversight
- $75,000 annual cash retainer plus $600,000 initial stock-option grant, vesting one-third annually over three years
- Eligible for annual equity awards currently totaling $400,000 in RSUs and stock-option grant-date value
- Standard indemnification and expense reimbursement reduce personal service-related risk for the new director
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders re-elected three Class I directors, including CEO Yvonne Greenstreet, through the 2029 annual meeting
- Elliott Sigal received the weakest support, with 12,844,836 votes against his re-election
- Executive compensation approved in advisory vote, with 111,772,389 votes for and 8,552,534 against
- PwC ratified as independent auditor for fiscal 2026, with 119,847,735 votes for
- 133,427,910 shares outstanding as of the March 25, 2026 record date
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alnylam Pharmaceuticals 8-K filings
Get the next ALNY 8-K as it lands
Follow ALNY for push alerts, or ask the research agent what this filing means.